Filarial antibody responses in Wuchereria bancrofti transmission area are related to parasitological but not clinical status.
Identifieur interne : 004D01 ( PubMed/Corpus ); précédent : 004D00; suivant : 004D02Filarial antibody responses in Wuchereria bancrofti transmission area are related to parasitological but not clinical status.
Auteurs : L. Nicolas ; S. Langy ; C. Plichart ; X. DeparisSource :
- Parasite immunology [ 0141-9838 ] ; 1999.
English descriptors
- KwdEn :
- Adult, Aged, Animals, Antibodies, Helminth (immunology), Diethylcarbamazine (therapeutic use), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (immunology), Elephantiasis, Filarial (parasitology), Female, Filaricides (therapeutic use), Humans, Immunoglobulin Isotypes (immunology), Ivermectin (therapeutic use), Male, Middle Aged, Wuchereria bancrofti (immunology).
- MESH :
- chemical , immunology : Antibodies, Helminth, Immunoglobulin Isotypes.
- chemical , therapeutic use : Diethylcarbamazine, Filaricides, Ivermectin.
- drug therapy : Elephantiasis, Filarial.
- immunology : Elephantiasis, Filarial, Wuchereria bancrofti.
- parasitology : Elephantiasis, Filarial.
- Adult, Aged, Animals, Female, Humans, Male, Middle Aged.
Abstract
In Wuchereria bancrofti transmission areas, three groups of individuals have been identified, according to the presence or absence of microfilariae or adult worm derived molecules in the blood compartment. These groups likely reflect individuals with different permissivity/resistance to the complete development of W. bancrofti cycle. The profile of filarial-specific immunoglobulins was analysed in W. bancrofti-exposed individuals in French Polynesia, according to the presence or absence of microfilariae (Mf) and adult worms, measured by Og4C3 circulating antigen. Individuals harbouring adult worms, have higher filarial-specific IgG4 but lower IgG3 and IgE levels, than adult worm-free individuals, independently of the presence of Mf. Low filarial-specific IgG1 and IgG2 levels were associated with the presence of Mf but independent of the presence/absence of adult worms. The filarial antibody responses were associated with the parasitological status of individuals but not with clinical symptoms such as hydroceles or limb lymphangitis or elephantiasis. The reduction of filarial-specific immunoglobulin levels was higher after treatment with diethylcarbamazine, than ivermectin, which likely reflects the better effect of the former on W. bancrofti adult worms. However, reduction of antibody levels was also observed in Mf-and adult worm-negative individuals. This could be due to the overall reduction of W. bancrofti transmission in the island where this study took place.
PubMed: 10101717
Links to Exploration step
pubmed:10101717Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Filarial antibody responses in Wuchereria bancrofti transmission area are related to parasitological but not clinical status.</title>
<author><name sortKey="Nicolas, L" sort="Nicolas, L" uniqKey="Nicolas L" first="L" last="Nicolas">L. Nicolas</name>
<affiliation><nlm:affiliation>Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti, French Polynesia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Langy, S" sort="Langy, S" uniqKey="Langy S" first="S" last="Langy">S. Langy</name>
</author>
<author><name sortKey="Plichart, C" sort="Plichart, C" uniqKey="Plichart C" first="C" last="Plichart">C. Plichart</name>
</author>
<author><name sortKey="Deparis, X" sort="Deparis, X" uniqKey="Deparis X" first="X" last="Deparis">X. Deparis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10101717</idno>
<idno type="pmid">10101717</idno>
<idno type="wicri:Area/PubMed/Corpus">004D01</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004D01</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Filarial antibody responses in Wuchereria bancrofti transmission area are related to parasitological but not clinical status.</title>
<author><name sortKey="Nicolas, L" sort="Nicolas, L" uniqKey="Nicolas L" first="L" last="Nicolas">L. Nicolas</name>
<affiliation><nlm:affiliation>Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti, French Polynesia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Langy, S" sort="Langy, S" uniqKey="Langy S" first="S" last="Langy">S. Langy</name>
</author>
<author><name sortKey="Plichart, C" sort="Plichart, C" uniqKey="Plichart C" first="C" last="Plichart">C. Plichart</name>
</author>
<author><name sortKey="Deparis, X" sort="Deparis, X" uniqKey="Deparis X" first="X" last="Deparis">X. Deparis</name>
</author>
</analytic>
<series><title level="j">Parasite immunology</title>
<idno type="ISSN">0141-9838</idno>
<imprint><date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Animals</term>
<term>Antibodies, Helminth (immunology)</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (immunology)</term>
<term>Elephantiasis, Filarial (parasitology)</term>
<term>Female</term>
<term>Filaricides (therapeutic use)</term>
<term>Humans</term>
<term>Immunoglobulin Isotypes (immunology)</term>
<term>Ivermectin (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Wuchereria bancrofti (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Helminth</term>
<term>Immunoglobulin Isotypes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Elephantiasis, Filarial</term>
<term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In Wuchereria bancrofti transmission areas, three groups of individuals have been identified, according to the presence or absence of microfilariae or adult worm derived molecules in the blood compartment. These groups likely reflect individuals with different permissivity/resistance to the complete development of W. bancrofti cycle. The profile of filarial-specific immunoglobulins was analysed in W. bancrofti-exposed individuals in French Polynesia, according to the presence or absence of microfilariae (Mf) and adult worms, measured by Og4C3 circulating antigen. Individuals harbouring adult worms, have higher filarial-specific IgG4 but lower IgG3 and IgE levels, than adult worm-free individuals, independently of the presence of Mf. Low filarial-specific IgG1 and IgG2 levels were associated with the presence of Mf but independent of the presence/absence of adult worms. The filarial antibody responses were associated with the parasitological status of individuals but not with clinical symptoms such as hydroceles or limb lymphangitis or elephantiasis. The reduction of filarial-specific immunoglobulin levels was higher after treatment with diethylcarbamazine, than ivermectin, which likely reflects the better effect of the former on W. bancrofti adult worms. However, reduction of antibody levels was also observed in Mf-and adult worm-negative individuals. This could be due to the overall reduction of W. bancrofti transmission in the island where this study took place.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10101717</PMID>
<DateCreated><Year>1999</Year>
<Month>05</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted><Year>1999</Year>
<Month>05</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0141-9838</ISSN>
<JournalIssue CitedMedium="Print"><Volume>21</Volume>
<Issue>2</Issue>
<PubDate><Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Parasite immunology</Title>
<ISOAbbreviation>Parasite Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Filarial antibody responses in Wuchereria bancrofti transmission area are related to parasitological but not clinical status.</ArticleTitle>
<Pagination><MedlinePgn>73-80</MedlinePgn>
</Pagination>
<Abstract><AbstractText>In Wuchereria bancrofti transmission areas, three groups of individuals have been identified, according to the presence or absence of microfilariae or adult worm derived molecules in the blood compartment. These groups likely reflect individuals with different permissivity/resistance to the complete development of W. bancrofti cycle. The profile of filarial-specific immunoglobulins was analysed in W. bancrofti-exposed individuals in French Polynesia, according to the presence or absence of microfilariae (Mf) and adult worms, measured by Og4C3 circulating antigen. Individuals harbouring adult worms, have higher filarial-specific IgG4 but lower IgG3 and IgE levels, than adult worm-free individuals, independently of the presence of Mf. Low filarial-specific IgG1 and IgG2 levels were associated with the presence of Mf but independent of the presence/absence of adult worms. The filarial antibody responses were associated with the parasitological status of individuals but not with clinical symptoms such as hydroceles or limb lymphangitis or elephantiasis. The reduction of filarial-specific immunoglobulin levels was higher after treatment with diethylcarbamazine, than ivermectin, which likely reflects the better effect of the former on W. bancrofti adult worms. However, reduction of antibody levels was also observed in Mf-and adult worm-negative individuals. This could be due to the overall reduction of W. bancrofti transmission in the island where this study took place.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicolas</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Institut Territorial de Recherches Médicales Louis Malardé, Papeete, Tahiti, French Polynesia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Langy</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Plichart</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Deparis</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Parasite Immunol</MedlineTA>
<NlmUniqueID>7910948</NlmUniqueID>
<ISSNLinking>0141-9838</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000909">Antibodies, Helminth</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005369">Filaricides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007132">Immunoglobulin Isotypes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>70288-86-7</RegistryNumber>
<NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber>
<NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000909" MajorTopicYN="N">Antibodies, Helminth</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007132" MajorTopicYN="N">Immunoglobulin Isotypes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year>
<Month>4</Month>
<Day>2</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1999</Year>
<Month>4</Month>
<Day>2</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1999</Year>
<Month>4</Month>
<Day>2</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">10101717</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004D01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:10101717 |texte= Filarial antibody responses in Wuchereria bancrofti transmission area are related to parasitological but not clinical status. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:10101717" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |